Evidence map›Paper›PMID 31758800›Full record

ArticleClinical pharmacology and therapeutics2020

The Patient Perspective: Putting the Patient at the Center of the Translational Innovation Process.

Leslie Wilson, Lawrence Lin, Kuldev Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Leslie WilsonDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
Lawrence LinDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Kuldev SinghByers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA.

Funding

UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD005978 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2016 to 2025
$34.5M
UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD004979 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2014 to 2016
$5.4M
FDA HHS U01 FD004979FDA HHS U01 FD005978
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Patient ParticipationTranslational Research, BiomedicalDiffusion of InnovationDrug ApprovalHumansNatalizumabOrganizational InnovationPatient PreferenceUnited StatesUnited States Food and Drug AdministrationUniversitiesNatalizumab

Identifiers

PMID31758800
PMCPMC9426754

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.